MA37941A1 - Dérivés d'aryléthynyle - Google Patents
Dérivés d'aryléthynyleInfo
- Publication number
- MA37941A1 MA37941A1 MA37941A MA37941A MA37941A1 MA 37941 A1 MA37941 A1 MA 37941A1 MA 37941 A MA37941 A MA 37941A MA 37941 A MA37941 A MA 37941A MA 37941 A1 MA37941 A1 MA 37941A1
- Authority
- MA
- Morocco
- Prior art keywords
- formula
- fluorophenyl
- compounds
- derivatives
- enantiome
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Epidemiology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La présente invention concerne des dérivés d'éthynyle de formule (i) dans laquelle • r est phényle, 3 -fluorophényle, 4-fluorophényle ou 2,5-di-fluorophényle, • ou un sel d'addition d'acide pharmaceutiquement acceptable, sous forme d'énantiome pur ayant la configuration absolue telle que représentée dans la formule (i). Il a été découvert de manière inattendue que les composés de formule générale i sont des modulateurs allostériques du récepteur de glutamate métabotropique de sous-type 5 (mglur5) qui sont utiles pour le traitement de la schizophrénie, des troubles cognitifs, du syndrome de l'x fragile ou de l'autisme et qui présentent des propriétés biochimiques, physico-chimiques et pharmacocinétiques avantageuses par rapport aux composés de l'art antérieur.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12186265 | 2012-09-27 | ||
| PCT/EP2013/069674 WO2014056710A1 (fr) | 2012-09-27 | 2013-09-23 | Dérivés d'aryléthynyle |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA37941A1 true MA37941A1 (fr) | 2016-04-29 |
| MA37941B1 MA37941B1 (fr) | 2016-11-30 |
Family
ID=47044829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37941A MA37941B1 (fr) | 2012-09-27 | 2015-03-20 | Dérivés d'aryléthynyle |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US9221802B2 (fr) |
| EP (1) | EP2900659B1 (fr) |
| JP (1) | JP6027251B2 (fr) |
| KR (1) | KR101737245B1 (fr) |
| CN (1) | CN104684911B (fr) |
| AR (1) | AR092673A1 (fr) |
| AU (1) | AU2013329739B2 (fr) |
| BR (1) | BR112015006218A2 (fr) |
| CA (1) | CA2885382A1 (fr) |
| CL (1) | CL2015000707A1 (fr) |
| CR (1) | CR20150139A (fr) |
| DK (1) | DK2900659T3 (fr) |
| EA (1) | EA025482B1 (fr) |
| ES (1) | ES2594031T3 (fr) |
| HK (1) | HK1207376A1 (fr) |
| HU (1) | HUE029636T2 (fr) |
| IL (1) | IL237596A (fr) |
| MA (1) | MA37941B1 (fr) |
| MX (1) | MX366136B (fr) |
| MY (1) | MY171743A (fr) |
| NZ (1) | NZ706283A (fr) |
| PE (1) | PE20150708A1 (fr) |
| PH (1) | PH12015500538A1 (fr) |
| PL (1) | PL2900659T3 (fr) |
| SG (1) | SG11201502449RA (fr) |
| SI (1) | SI2900659T1 (fr) |
| TW (1) | TWI476194B (fr) |
| UA (1) | UA113779C2 (fr) |
| WO (1) | WO2014056710A1 (fr) |
| ZA (1) | ZA201501678B (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA113223C2 (xx) * | 2012-08-13 | 2016-12-26 | Арилетинілпіримідини | |
| CN104603110B (zh) * | 2012-10-18 | 2016-08-31 | 霍夫曼-拉罗奇有限公司 | 作为mGluR5受体活性的调节剂的乙炔基衍生物 |
| SI3303316T1 (sl) | 2015-06-03 | 2020-07-31 | F. Hoffmann-La Roche Ag | Derivati etinila |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| EP1809620B1 (fr) | 2004-11-04 | 2010-12-29 | Addex Pharma SA | Nouveaux derives de tetrazole utilises comme modulateurs allosteriques positifs des recepteurs de glutamate metabotropiques |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| TW200811157A (en) * | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators I |
| AU2008259776A1 (en) | 2007-06-03 | 2008-12-11 | Vanderbilt University | Benzamide mGluR5 positive allosteric modulators and methods of making and using same |
| US8034806B2 (en) * | 2007-11-02 | 2011-10-11 | Vanderbilt University | Bicyclic mGluR5 positive allosteric modulators and methods of making and using same |
| TW201116532A (en) * | 2009-08-05 | 2011-05-16 | Merz Pharma Gmbh & Co Kgaa | Metabotropic glutamate receptor modulators |
| US8586581B2 (en) * | 2009-12-17 | 2013-11-19 | Hoffmann-La Roche Inc | Ethynyl compounds useful for treatment of CNS disorders |
| US8420661B2 (en) * | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
-
2013
- 2013-09-23 PE PE2015000422A patent/PE20150708A1/es active IP Right Grant
- 2013-09-23 EA EA201590557A patent/EA025482B1/ru not_active IP Right Cessation
- 2013-09-23 NZ NZ706283A patent/NZ706283A/en not_active IP Right Cessation
- 2013-09-23 AU AU2013329739A patent/AU2013329739B2/en not_active Ceased
- 2013-09-23 MX MX2015003560A patent/MX366136B/es active IP Right Grant
- 2013-09-23 ES ES13766286.2T patent/ES2594031T3/es active Active
- 2013-09-23 EP EP13766286.2A patent/EP2900659B1/fr active Active
- 2013-09-23 UA UAA201503791A patent/UA113779C2/uk unknown
- 2013-09-23 CN CN201380050037.9A patent/CN104684911B/zh active Active
- 2013-09-23 CA CA2885382A patent/CA2885382A1/fr not_active Abandoned
- 2013-09-23 HU HUE13766286A patent/HUE029636T2/en unknown
- 2013-09-23 MY MYPI2015000777A patent/MY171743A/en unknown
- 2013-09-23 WO PCT/EP2013/069674 patent/WO2014056710A1/fr active Application Filing
- 2013-09-23 PL PL13766286T patent/PL2900659T3/pl unknown
- 2013-09-23 BR BR112015006218A patent/BR112015006218A2/pt not_active IP Right Cessation
- 2013-09-23 SG SG11201502449RA patent/SG11201502449RA/en unknown
- 2013-09-23 SI SI201330373A patent/SI2900659T1/sl unknown
- 2013-09-23 KR KR1020157010351A patent/KR101737245B1/ko active IP Right Grant
- 2013-09-23 DK DK13766286.2T patent/DK2900659T3/en active
- 2013-09-23 JP JP2015533547A patent/JP6027251B2/ja active Active
- 2013-09-25 AR ARP130103433A patent/AR092673A1/es unknown
- 2013-09-26 TW TW102134845A patent/TWI476194B/zh not_active IP Right Cessation
-
2015
- 2015-03-05 IL IL237596A patent/IL237596A/en active IP Right Grant
- 2015-03-11 ZA ZA2015/01678A patent/ZA201501678B/en unknown
- 2015-03-12 PH PH12015500538A patent/PH12015500538A1/en unknown
- 2015-03-16 CR CR20150139A patent/CR20150139A/es unknown
- 2015-03-20 MA MA37941A patent/MA37941B1/fr unknown
- 2015-03-20 CL CL2015000707A patent/CL2015000707A1/es unknown
- 2015-03-26 US US14/669,653 patent/US9221802B2/en active Active
- 2015-08-19 HK HK15108049.7A patent/HK1207376A1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA41134A (fr) | Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales | |
| TN2014000147A1 (fr) | Derives de (4-phenylimidazol-2-yl) ethylamine utiles comme modulateurs de canal sodique | |
| MA38080A1 (fr) | Dérivés substitués de phtalazin-1(2h)-one comme inhibiteurs sélectifs de la poly(adp-ribose) polymérase-1 | |
| MX2008010671A (es) | Derivados de cinolina como inhibidores de fosfodiesterasa 10. | |
| MX2009013733A (es) | Nuevos derivados de acido dicarboxilico como agonistas de los receptores de s1p1. | |
| MA38323A1 (fr) | Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale | |
| NZ603108A (en) | 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators | |
| TN2015000547A1 (fr) | Composes heteroaromatiques et leur utilisation comme ligands de dopamine d1 | |
| WO2009025839A3 (fr) | Inhibiteurs de phosphodiestérase 10 | |
| MA31834B1 (fr) | 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, leur procédé de production et leur utilisation comme anti-inflammatoires | |
| MA35444B1 (fr) | Ligands du récepteur ep1 | |
| TN2016000188A1 (fr) | Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs. | |
| MX2009013885A (es) | Derivados de quinolina fusionados utiles como moduladores de acido gamma-aminobutirico. | |
| MX337443B (es) | Derivados de etinilo como moduladores alostericos positivos del receptor de glutamato metabotropico del subtipo 5 (mglur5). | |
| MA37941B1 (fr) | Dérivés d'aryléthynyle | |
| UA103329C2 (ru) | Соли соединений-ингибиторов вич | |
| MA34173B1 (fr) | Hhétérobiaryl-cyclohexyl-tétraazabenzo[e]azulènes | |
| EA014959B3 (ru) | Ингибиторы глицинового переносчика-1 | |
| MA31863B1 (fr) | Dérivés de pyrazole comme inhibiteurs de 5-lo | |
| MA38659B1 (fr) | Dérivés éthynyle comme antagonistes du récepteur métabotrope du glutamate | |
| TN2012000285A1 (fr) | NOUVEAUX DERIVES D' (HETEROCYCLE-PIPERIDINE CONDENSEE)-(PIPERAZINYL)-1-ALCANONE OU D' (HETEROCYCLE-PYRROLIDINE CONDENSEE)-(PIPERAZINYL)-1-ALCANONE ET LEUR UTILISATION COMME INHIBITEURS DE p75 | |
| IN2013DN02555A (fr) | ||
| MX2012001799A (es) | Derivados de pirrolidina como antagonistas del receptor de neuroquinona 3 (nk3). | |
| MA38011B1 (fr) | Dérivés d'éthynyle comme modulateurs de l'activité du récepteur mglur5 | |
| PH12015500261A1 (en) | Arylethynyl pyrimidines |